Teva settles Austedo patent dispute with Aurobindo

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) and its affiliates have reached an agreement with Indian drugmaker Aurobindo Pharma (BSE: 524804) to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (ANDA) for a generic deutetrabenazine product, a copy of the branded drug Austedo.

Teva and Aurobindo have been involved in a patent infringement litigation in which Teva asserted a number of patents against Aurobindo that cover Teva’s Austedo product.

Can sell generic product beginning April 2033